CEDAR KNOLLS, NJ -- (Marketwired) -- 03/08/16 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that at a special meeting of the Company's stockholders held on March 3, 2016, the Company's stockholders elected Ren Ren, Bin Zhou, Zhengguang Lyu, Guiying Zhao and K. Bryce Toussaint to serve as new members of the Company's Board of Directors in connection with the initial closing of the strategic investment by RENS Technology Inc. ("RENS") in the Company. The new directors will join the Company's existing directors, Dr. Robert J. Hariri, Dr. Louis J. Aronne, Mr. Christopher Pechock and Mr. Joseph Mannello, on the Company's nine-member board. Mr. Ren Ren, founder and chairman of RENS Agriculture Science and Technology Co, Ltd., the parent company of RENS, assumed the newly-created position of Global Chairman of the Company.
Mr. Ren Ren, Global Chairman of the Company, commented, "The new directors bring significant world-class experience, including global marketing, product development, pharmaceutical and food technology experience. We look forward to working together with the Company's existing directors and executive management team to expand the Company's market opportunities and global footprint."
About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin reducing agent. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin levels, inflammatory cytokine levels and cholesterol levels, the successful launch and customer demand for our Rē Muscle Health™ and other products, the closing of the second and third tranches of the recent financing with RENS (the "Financing"), the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, including the successful expansion through the distribution efforts with RENS, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, including closing the second and third tranches of the Financing and through the exercise of the warrants issued in the Financing, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin® and Rē Muscle Health™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities including finding suitable manufacturing partners in China and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, the ability to acquire suitable acquisition targets, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
Chief Financial Officer
Source: MYOS Corporation